Literature DB >> 28543693

Somatic driver mutations in melanoma.

Bobby Y Reddy1, David M Miller1,2, Hensin Tsao1.   

Abstract

Melanoma has one of the highest somatic mutational burdens among solid malignancies. Although the rapid progress in genomic research has contributed immensely to our understanding of the pathogenesis of melanoma, the clinical significance of the vast array of genomic alterations discovered by next-generation sequencing is far from being fully characterized. Most mutations prevalent in melanoma are simply neutral "passengers," which accompany functionally significant "drivers" under transforming conditions. The delineation of driver mutations from passenger mutations is critical to the development of targeted therapies. Novel advances in genomic data analysis have aided in distinguishing true driver mutations involved in tumor progression. Here, the authors review the current literature on important somatic driver mutations in melanoma, along with the implications for treatment. Cancer 2017;123:2104-17.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  driver mutations; genetics; immune therapy; melanoma; targeted therapy

Mesh:

Substances:

Year:  2017        PMID: 28543693     DOI: 10.1002/cncr.30593

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  36 in total

1.  Heme oxygenase promotes B-Raf-dependent melanosphere formation.

Authors:  Kimberly J Jasmer; Jie Hou; Philip Mannino; Jianlin Cheng; Mark Hannink
Journal:  Pigment Cell Melanoma Res       Date:  2020-07-09       Impact factor: 4.693

Review 2.  Novel Immunotherapy Combinations.

Authors:  Babar Bashir; Melissa A Wilson
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

3.  FBXW7 regulates a mitochondrial transcription program by modulating MITF.

Authors:  Franco Abbate; Brateil Badal; Karen Mendelson; Iraz T Aydin; Madhavika N Serasinghe; Ramiz Iqbal; Jarvier N Mohammed; Alexander Solovyov; Benjamin D Greenbaum; Jerry E Chipuk; Julide T Celebi
Journal:  Pigment Cell Melanoma Res       Date:  2018-04-29       Impact factor: 4.693

Review 4.  Genetics of metastasis: melanoma and other cancers.

Authors:  Noel Turner; Olivia Ware; Marcus Bosenberg
Journal:  Clin Exp Metastasis       Date:  2018-05-02       Impact factor: 5.150

Review 5.  Germline mutations predisposing to melanoma.

Authors:  Atrin Toussi; Nicole Mans; Jeanna Welborn; Maija Kiuru
Journal:  J Cutan Pathol       Date:  2020-05-11       Impact factor: 1.587

6.  Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.

Authors:  Cristina Pellegrini; Ludovica Cardelli; Marina De Padova; Lucia Di Nardo; Valeria Ciciarelli; Tea Rocco; Gianluca Cipolloni; Marco Clementi; Alessio Cortellini; Alessandra Ventura; Pietro Leocata; Maria Concetta Fargnoli
Journal:  Acta Derm Venereol       Date:  2020-01-23       Impact factor: 3.875

7.  A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.

Authors:  Baptiste Louveau; Fanélie Jouenne; Céleste Lebbe; Samia Mourah; Pauline Têtu; Aurélie Sadoux; Aurélia Gruber; Eddie Lopes; Julie Delyon; Kevin Serror; Oren Marco; Laetitia Da Meda; Aminata Ndiaye; Alban Lermine; Nicolas Dumaz; Maxime Battistella; Barouyr Baroudjian
Journal:  Target Oncol       Date:  2020-12       Impact factor: 4.493

Review 8.  Rac1, A Potential Target for Tumor Therapy.

Authors:  Jiaxin Liang; Linda Oyang; Shan Rao; Yaqian Han; Xia Luo; Pin Yi; Jinguan Lin; Longzheng Xia; Jiaqi Hu; Shiming Tan; Lu Tang; Qing Pan; Yanyan Tang; Yujuan Zhou; Qianjin Liao
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

Review 9.  Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas.

Authors:  Jiri Vachtenheim; Lubica Ondrušová
Journal:  Life (Basel)       Date:  2021-05-05

10.  Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.

Authors:  Chi Yan; Nabil Saleh; Jinming Yang; Caroline A Nebhan; Anna E Vilgelm; E Premkumar Reddy; Joseph T Roland; Douglas B Johnson; Sheau-Chiann Chen; Rebecca L Shattuck-Brandt; Gregory D Ayers; Ann Richmond
Journal:  Mol Cancer       Date:  2021-06-06       Impact factor: 41.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.